Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman

SAN FRANCISCO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Hagens Berman is investigating claims alleged in a new securities class action against Replimune Group, Inc. (NASDAQ: REPL) and its executives after the company's stock plummeted following the FDA’s rejection of its leading cancer drug, RP1. The lawsuit alleges that Replimune misled investors by overstating the drug’s trial data and failing to disclose critical regulatory risks. The filing, known as Jboor v. Replimune Group, Inc., et al., is on behalf of inve ...